By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


Company News
Hemispherx (HEB) Exploring Possible Research Programs In Zika Virus Modeled On A Prior Alferon N Clinical Trial On Closely Related Flavivirus (West Nile) 2/9/2016 7:55:47 AM
Hemispherx (HEB) Introduces A Voluntary Stock Purchase Plan To Create Shareholder Value 2/3/2016 8:09:39 AM
Flooding Damages Hemispherx (HEB)'s Newly-Renovated North Jersey Plant 1/26/2016 6:54:36 AM
Hemispherx (HEB) Boss Returns Shares After Stock Snafu 12/31/2015 8:26:02 AM
Hemispherx (HEB) Announces Financial Results For The Nine Months Ended September 30, 2015 11/17/2015 8:15:40 AM
New Arrowhead Analyst Issues Updated Diligence And Valuation Report On Hemispherx (HEB) 9/30/2015 7:23:34 AM
Hemispherx (HEB) Receives The European Patent Office Grant Of New Composition Of Matter Patent Covering Ampligen Formulations 9/28/2015 7:40:20 AM
Hemispherx (HEB) Reports Article By Senior Authors From Italian Ministry Of Health And Related Agencies Suggesting Broad Applicability Of Ampligen To Multiple Sclerosis 9/23/2015 7:28:10 AM
Hemispherx (HEB) Research Team Identifies Characteristics Of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive Of Improved Response To Ampligen 9/21/2015 8:53:01 AM
Hemispherx (HEB) Announces Patient Assistance Program For Chronic Fatigue Syndrome Open Label Study 9/17/2015 8:24:04 AM